Insulet (PODD) to Release Quarterly Earnings on Thursday

Insulet (NASDAQ:PODD) is set to announce its earnings results after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of $0.56 per share for the quarter. Insulet has set its FY 2024 guidance at EPS and its Q2 2024 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.34. The business had revenue of $441.70 million for the quarter, compared to analysts’ expectations of $424.05 million. Insulet had a return on equity of 34.06% and a net margin of 13.14%. Insulet’s quarterly revenue was up 23.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.23 earnings per share. On average, analysts expect Insulet to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Insulet Stock Performance

PODD opened at $196.35 on Wednesday. The stock has a market cap of $13.75 billion, a PE ratio of 59.50, a P/E/G ratio of 3.55 and a beta of 1.16. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. Insulet has a 1 year low of $125.82 and a 1 year high of $265.69. The stock’s 50 day simple moving average is $195.32 and its 200-day simple moving average is $184.05.

Wall Street Analysts Forecast Growth

Several analysts recently commented on PODD shares. Raymond James decreased their price target on Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research note on Friday, May 10th. Wolfe Research raised Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price target on the stock in a research note on Tuesday, May 7th. Redburn Atlantic began coverage on Insulet in a research note on Thursday, May 30th. They set a “buy” rating and a $235.00 price target on the stock. Jefferies Financial Group upped their price target on Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, May 10th. Finally, OTR Global reaffirmed a “mixed” rating on shares of Insulet in a research note on Monday, June 10th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average price target of $239.18.

Insider Transactions at Insulet

In other news, SVP Mark N. Field sold 2,131 shares of the company’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $190.43, for a total transaction of $405,806.33. Following the completion of the transaction, the senior vice president now directly owns 14,375 shares of the company’s stock, valued at $2,737,431.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Mark N. Field sold 1,500 shares of the stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $199.96, for a total transaction of $299,940.00. Following the transaction, the senior vice president now owns 12,875 shares in the company, valued at $2,574,485. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Mark N. Field sold 2,131 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $190.43, for a total value of $405,806.33. Following the transaction, the senior vice president now owns 14,375 shares in the company, valued at approximately $2,737,431.25. The disclosure for this sale can be found here. Insiders sold 13,931 shares of company stock valued at $2,636,286 over the last three months. Company insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.